menu

Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma

close
0.25 credits
15 mintues
Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    The anti-CD20 antibody rituximab has been the backbone of initial treatment of follicular lymphoma (FL) as a single agent or in a variety of combination regimens. Although rituximab produces durable responses, the pathobiology of FL is heterogeneous and relapses are common. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control. 

    Fortunately, the treatment of relapsed/refractory FL in the second line and beyond is undergoing a transformation, with multiple agents with novel mechanisms of action recently approved or in late-stage clinical trials. As evidence-based guidelines evolve with the changing treatment landscape, it is more crucial than ever for clinicians to understand the safety and efficacy of newly approved and emerging novel agents for relapsed/refractory FL, and individualize treatment based on patient- and disease-related factors.

    AXIS routinely collects and analyzes data gathered from participants in our live grand rounds activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent virtual grand rounds series on relapsed/refractory follicular lymphoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Apply clinical data and prognostic tools to predict for PFS and early treatment failure after frontline immunochemotherapy
    • Interpret the association of immune-related toxicity with PI3K inhibitors and improved treatment response
    • Assess recent evidence to inform the optimal timing of autologous stem cell transplant for patients with relapsed/refractory follicular lymphoma
    • Evaluate recent evidence for the use of PD-1/PD-L1 inhibitors in relapsed/refractory follicular lymphoma
  • Target Audience

    This activity is intended for hematologists, oncologists, advanced practitioners, oncology nurses, physician assistants, pharmacists, and other healthcare professionals who treat patients with relapsed/refractory follicular lymphoma.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty Ajay K. Gopal, MD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Ajay K. Gopal, MD reported a financial interest/relationship or affiliation in the form of Advisor: Seattle Genetics, Inc; Acerta Pharma; Actinium Pharmaceuticals, Inc; Aptevo Therapeutics; Complement Pharma; Gilead; I-Mab Biopharma; Janssen Oncology; and Takeda Oncology. Contracted research: Janssen Oncology; Merck & Co, Inc; Pfizer, Inc; Seattle Genetics, Inc; Takeda Oncology; Teva Neuroscience, Inc; Bristol-Myers Squibb Co; and eFFECTOR Therapeutics.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 12/7/2021. PAs should only claim credit commensurate with the extent of their participation

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.25 contact hours of continuing pharmacy education credit JA4008106-0000-20-078-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from Celgene Corp; Gilead Sciences, Inc; Incyte Corp; and Verastem Oncology.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The anti-CD20 antibody rituximab has been the backbone of initial treatment of follicular lymphoma (FL) as a single agent or in a variety of combination regimens. Although rituximab produces durable responses, the pathobiology of FL is heterogeneous and relapses are common. Patients who present with earlier relapse are particularly challenging to treat because they often have more aggressive disease and will be exposed to multiple lines of therapy to attain disease control. 

    Fortunately, the treatment of relapsed/refractory FL in the second line and beyond is undergoing a transformation, with multiple agents with novel mechanisms of action recently approved or in late-stage clinical trials. As evidence-based guidelines evolve with the changing treatment landscape, it is more crucial than ever for clinicians to understand the safety and efficacy of newly approved and emerging novel agents for relapsed/refractory FL, and individualize treatment based on patient- and disease-related factors.

    AXIS routinely collects and analyzes data gathered from participants in our live grand rounds activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent virtual grand rounds series on relapsed/refractory follicular lymphoma.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Apply clinical data and prognostic tools to predict for PFS and early treatment failure after frontline immunochemotherapy
    • Interpret the association of immune-related toxicity with PI3K inhibitors and improved treatment response
    • Assess recent evidence to inform the optimal timing of autologous stem cell transplant for patients with relapsed/refractory follicular lymphoma
    • Evaluate recent evidence for the use of PD-1/PD-L1 inhibitors in relapsed/refractory follicular lymphoma
  • Target Audience

    This activity is intended for hematologists, oncologists, advanced practitioners, oncology nurses, physician assistants, pharmacists, and other healthcare professionals who treat patients with relapsed/refractory follicular lymphoma.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty Ajay K. Gopal, MD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Ajay K. Gopal, MD reported a financial interest/relationship or affiliation in the form of Advisor: Seattle Genetics, Inc; Acerta Pharma; Actinium Pharmaceuticals, Inc; Aptevo Therapeutics; Complement Pharma; Gilead; I-Mab Biopharma; Janssen Oncology; and Takeda Oncology. Contracted research: Janssen Oncology; Merck & Co, Inc; Pfizer, Inc; Seattle Genetics, Inc; Takeda Oncology; Teva Neuroscience, Inc; Bristol-Myers Squibb Co; and eFFECTOR Therapeutics.

    The planners, managers and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING EDUCATION
    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 12/7/2021. PAs should only claim credit commensurate with the extent of their participation

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.25 contact hours of continuing pharmacy education credit JA4008106-0000-20-078-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by educational grants from Celgene Corp; Gilead Sciences, Inc; Incyte Corp; and Verastem Oncology.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer 
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit: 
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/6/21